Journal article
1582P Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Abstract
Background Novel therapies are replacing established treatment options for patients with advanced non-small cell lung cancer (aNSCLC), which poses a challenge to healthcare budgets. The impact of Treatment Evolution in NSCLC (iTEN) model is a validated discrete event patient simulation designed to estimate the impact of treatment sequencing in aNSCLC. The impact of five novel therapies (osimertinib, alectinib, brigatinib, dabrafenib and …
Authors
Cheema PK; Evans WK; Burkes R; Sangha R; Ho C; Wheatley-Price P; Boehm D; Venkatesh J; Walisser S; Grima D
Journal
Annals of Oncology, Vol. 30, , pp. v651–v652
Publisher
Elsevier
Publication Date
10 2019
DOI
10.1093/annonc/mdz260.104
ISSN
0923-7534